VERAXA Biotech (NASDAQ: VRXA), a Switzerland-based biotechnology company with a key financial and regulatory presence in the U.S., is expanding its use of human-relevant testing methods across its oncology research programs. The company aims to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The move, detailed in an October 7, 2026, company announcement, centers on the implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays and computational modeling, according to a company press release distributed via NEWMEDIAWIRE.
The strategy is aligned with U.S. Food and Drug Administration (FDA) guidance and is being applied across VERAXA's preclinical research programs. The company says the approach is intended to improve the relevance of experimental findings to human biology while reducing reliance on animal testing. For readers and industry observers, the announcement matters because it signals a potential shift in how early-stage cancer therapies are evaluated, potentially accelerating drug development timelines and lowering costs while addressing ethical concerns about animal use. VERAXA is applying these methods to support the development of its BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA's models to assess the dual-target specificity of its lead T-cell engager candidates. In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company says approximately 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company reports that its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. These findings, if validated, could bolster confidence in VERAXA's pipeline and provide a more efficient path to clinical trials.
VERAXA Biotech, described as an emerging leader in designing novel cancer therapies, is listed on the Nasdaq under the ticker VRXA. Investors and industry watchers can find more information about the company through its VERAXA Biotech (NASDAQ: VRXA) profile. The company's forward-looking statements involve risks and uncertainties, and actual results may differ materially. For full details, see the complete announcement at Read More. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
